

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

EQUALITY IMPACT ASSESSMENT

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NICE guidelines

Equality impact assessment

Meningitis (bacterial) and meningococcal septicaemia in children and young people: recognition, diagnosis and management

The impact on equality has been assessed during guidance development according to the principles of the NICE equality policy.

1.0 Checking for updates and scope: before scope consultation (to be completed by the Developer and submitted with the draft scope for consultation)

1.1 Have any potential equality issues been identified during the check for an update or during development of the draft scope, and, if so, what are they?

(Please specify if the issue has been highlighted by a stakeholder)

Potential inequalities have been identified during scoping relating to the treatment of babies, children and young people with meningitis (bacterial) and meningococcal septicaemia for the following groups:

- Babies, children and young people with dark skin, for example of African, African-Caribbean, Middle Eastern and South Asian origin, as the detection of the typical rash associated with meningococcal disease can be harder to identify on dark skin.
- Babies, children and young people from disadvantaged socio-economic backgrounds, who are at increased risk of meningitis.

- Babies, children and young people who have recently come from countries or events (such as the Hajj) where there is an increased risk of developing meningococcal disease.

1.2 What is the preliminary view on the extent to which these potential equality issues need addressing by the Committee?

The committee will examine the evidence to see if it supports making differential recommendations based solely on the groups identified above.

It is likely that for certain questions the Committee will want to consider specific recommendations for particular population groups.

Completed by Developer: Vanessa Delgado Nunes

Date: 14 November 2019

Approved by NICE quality assurance lead: Kay Nolan

Date: 25 November 2019